The DROFEN Turnkey CDMO Framework: 8 Integrated Capabilities for Injection Pen Manufacturing
The global injection delivery device market is undergoing a seismic transformation. With over 537 million people living with diabetes worldwide-a number projected to reach 783 million by 2045-the demand for reliable, affordable, and regulatory-compliant injection pen devices has never been greater [1]. At the same time, the imminent patent expiration of blockbuster metabolic and weight-management biologics is opening a multi-billion-dollar window for pharmaceutical manufacturers seeking to enter the injectable drug-device combination space.
Yet for most pharmaceutical companies, the path from a product concept to a market-ready injection pen is riddled with complexity: industrial design, patent clearance, mold tooling, component manufacturing, aseptic filling, automated assembly, and regulatory submission-each stage requiring deep specialization, capital investment, and years of experience.
DROFEN MACHINERY was built precisely to eliminate this complexity. As a vertically integrated Turnkey CDMO (Contract Development and Manufacturing Organization) equipment partner, DROFEN provides a single-source, end-to-end solution. Driven by our core philosophy to "Make Customer Great Again", we take pharmaceutical partners from the drawing board to commercial production, equipping them to lead in highly regulated global markets.
The Market Opportunity: Why Now Is the Time to Act
The injection pen market is forecast to grow at a CAGR of 9.2% through 2030. This growth is being driven by three converging forces:
1.The global diabetes epidemic continues to expand, particularly in the Asia-Pacific and Middle East regions.
2.The shift from vial-and-syringe administration to pen-based delivery is accelerating, driven by patient preference for convenience and dosing accuracy.
3.The biosimilar revolution is democratizing access to advanced therapies. Companies are now entering the market with biosimilar metabolic and biological products, requiring massive new manufacturing capacity.
Pharmaceutical manufacturers in emerging markets are actively seeking equipment partners who can help them establish aseptic fill-finish and device assembly capabilities-and they need to move fast.
DROFEN's Turnkey CDMO Framework: Eight Integrated Capabilities
What sets DROFEN apart from conventional equipment vendors is the depth and integration of our service portfolio. Rather than supplying isolated machines, DROFEN engineers complete production ecosystems. The following eight capabilities form the backbone of DROFEN's CDMO offering.
1. Industrial Design & Regulatory Strategy
Every successful injection pen begins with a design that is both ergonomically sound and legally defensible. DROFEN's engineering team conducts comprehensive Freedom-to-Operate (FTO) analysis across global patent databases, identifying existing claims held by major device manufacturers. Based on this analysis, DROFEN develops original pen architectures that are specifically engineered to avoid infringement in target markets.
DROFEN's industrial designers apply principles of human factors engineering (HFE) in accordance with IEC 62366-1, ensuring the final device meets the usability requirements demanded by FDA and EMA reviewers.
2. High-Precision In-House Mold Development
The transition from design to physical product requires tooling of exceptional precision. A capability most pure machine builders lack, DROFEN operates a dedicated in-house mold engineering center. Pen components are manufactured to tolerances measured in microns.
All molds undergo rigorous Mold Flow Analysis (MFA) prior to cutting. Critically, DROFEN retains full ownership of the mold design IP on behalf of its clients, ensuring that tooling assets remain proprietary and cannot be replicated by competing manufacturers.
3. GMP Injection Molding of Pen Components
With validated molds in hand, DROFEN's ISO Class 8 cleanroom injection molding facility produces all pen components from medical-grade polymers. Each production batch is accompanied by full material traceability. Biocompatibility testing in accordance with ISO 10993 is conducted for all materials, ensuring compliance with both FDA 21 CFR Part 820 and EU MDR 2017/745 requirements.
4. Aseptic Filling & High-Speed Inspection
The filling of biological drug solutions into cartridges or pre-filled syringes (PFS) represents a technically demanding stage. DROFEN's aseptic filling lines are designed to the highest standards of contamination control (ISO Class 5/Grade A).
For clients utilizing PP plastic pre-filled syringes, DROFEN provides industry-leading filling lines capable of 300 units per minute (8-head configuration). To perfectly match this speed, DROFEN engineered the world's first fully automated AI Light Inspection Machine for PP syringes, achieving an extraordinary 330 units per minute to ensure quality control is never a production bottleneck.
|
Drug Category |
Container Format |
DROFEN Solution |
|
Rapid/Long-acting therapies |
3ml glass cartridge |
Cartridge Filling Line |
|
Advanced metabolic biologics |
3ml glass cartridge / PP Syringe |
High-Speed PFS Line (300 units/min) |
|
Combination products |
Custom formats |
Flexible Aseptic Filling |
5. Automated Injection Pen Assembly Lines
Once components are molded and cartridges are filled, DROFEN's automated assembly lines bring the complete pen device together with speed, precision, and full traceability. Each assembly line is engineered to deliver a highly stable, industry-leading output of 160 units per minute (approx. 9,600 pens per hour).
Key assembly operations-including cartridge loading, dose dial installation, and cap fitting-are performed by servo-driven robotic stations. 100% In-Line Functional Testing is non-negotiable: every assembled pen undergoes torque testing and dose accuracy verification without slowing down the 160 units/min output.
6. Drug-Device Combination Final Packaging
The final stage involves loading the tested pen device into its secondary packaging. DROFEN supplies complete packaging lines capable of handling blister packs and folding cartons, with integrated checkweighing, vision inspection, and serialization in compliance with the EU Falsified Medicines Directive (FMD) and US DSCSA track-and-trace requirements.
7. GMP Compliance & Quality Systems (Expanding to CRO)
For pharmaceutical companies entering regulated markets, the regulatory pathway can be daunting. DROFEN's quality team provides comprehensive support across the full submission lifecycle, including IQ/OQ/PQ validation and cGMP gap assessments.
Looking to the future, DROFEN is actively expanding its capabilities to offer CRO (Contract Research Organization) support and comprehensive GMP compliance consulting, positioning us as a true full-chain partner.
8. Global Market Entry & Localized Support
DROFEN's partnership model extends beyond the factory floor. With a dedicated branch office in India and a global engineering team, we provide rapid 24-48 hour on-site support during equipment qualification, process validation, and commercial production ramp-up.
Why Pharmaceutical Companies Choose DROFEN
The decision to partner with a Turnkey CDMO is ultimately a decision about risk mitigation and speed. DROFEN's value proposition rests on four pillars:
•Single-Source Accountability: Eliminates the coordination burden and finger-pointing that arise when design, tooling, and manufacturing are distributed across multiple vendors.
•Speed to Market: DROFEN's integrated workflow-from design freeze to commercial equipment delivery-can be completed in 6 to 9 months, compared to the 18+ months typically required when working with fragmented suppliers.
•Proven Track Record: DROFEN's processes and documentation withstand scrutiny from stringent regulatory authorities, with successful installations across Asia, the Middle East, and beyond.
•Unmatched Production Speed: With 300 units/min PFS filling, 330 units/min inspection, and 160 units/min pen assembly, DROFEN delivers the true commercial scale required to dominate the biosimilar market.
A Partnership Built for the Future
The pharmaceutical companies that will lead the next decade are those that invest today in the manufacturing capabilities needed to deliver high-quality injectable devices at scale. DROFEN MACHINERY is committed to being the equipment partner of choice for these companies-providing the engineering expertise and Turnkey solutions needed to turn a product concept into a global commercial success.
Ready to accelerate your injection pen manufacturing?Contact DROFEN MACHINERY today to discuss your Turnkey CDMO requirements.
📧 info@drofen-pharma.com | 📞 +86 189 3004 6646 | 🌐 www.drofen-pharma.com
References[1]: # "International Diabetes Federation. (2021). IDF Diabetes Atlas, 10th edn. Brussels, Belgium."
Related Technical Resources
